Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials

被引：0
|
作者：
Amy McMichael
Seemal R. Desai
Aamir Qureshi
Shipra Rastogi
Andrew F. Alexis
机构：
[1] Wake Forest Baptist Medical Center,Department of Dermatology
[2] Medical Center Boulevard,undefined
[3] Innovative Dermatology,undefined
[4] University of Texas Southwestern Medical Center,undefined
[5] Ortho Dermatologics,undefined
[6] Mount Sinai St. Luke’s and Mount Sinai West,undefined
来源：
American Journal of Clinical Dermatology | 2019年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：267 / 276
页数：9
相关论文
共 50 条
  • [31] Safety of tildrakizumab for moderate-to-severe chronic plaque psoriasis: Pooled analysis of three randomized controlled studies
    Blauvelt, Andrew
    Reich, Kristian
    Papp, Kim A.
    Kimball, Alexa B.
    Gooderham, Melinda
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Li, Qing
    la Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB252 - AB252
  • [32] Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study
    Nakagawa, Hidemi
    Niiro, Hiroaki
    Ootaki, Kenji
    JOURNAL OF DERMATOLOGICAL SCIENCE, 2016, 81 (01) : 44 - 52
  • [33] Effects of apremilast on pruritus in patients with moderate-to-severe plaque psoriasis: results from the ESTEEM 1 and 2 trials
    Papp, K.
    Yosipovitch, G.
    Bagel, J.
    Kircik, L.
    Thaci, D.
    Lambert, J.
    Ferrandiz, C.
    Goodfield, M.
    Hu, C. C.
    Stevens, R.
    Day, R.
    Girolomoni, G.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E144 - E145
  • [34] RISANKIZUMAB EFFICACY/SAFETY IN MODERATE-TO-SEVERE PLAQUE PSORIASIS: 16-WEEK RESULTS FROM IMMHANCE
    Blauvelt, Andrew
    Papp, Kim A.
    Gooderham, Melinda
    Langley, Richard G.
    Leonardi, Craig
    Lacour, Jean-Philippe
    Philipp, Sandra
    Tyring, Stephen
    Bukhalo, Michael
    Wu, Jashin J.
    Bagel, Jerry
    Frankel, Ellen H.
    Pariser, David
    Flack, Mary
    Scherer, Joseph
    Geng, Ziqian
    Gu, Yihua
    Camez, Anne
    Thompson, Elizabeth H. Z.
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 30 - 30
  • [35] Efficacy and safety of tofacitinib for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials
    Kuo, C. -M.
    Tung, T. -H.
    Wang, S. -H.
    Chi, C. -C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (03) : 355 - 362
  • [36] Efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study
    Van Voorhees, A. S.
    Stein Gold, L.
    Lebwohl, M.
    Strober, B.
    Sofen, H.
    Papp, K.
    Bagel, J.
    Zhang, Z.
    Paris, M.
    Wang, Y.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (04) : 840 - 842
  • [37] Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial
    Fiorillo, Loretta
    Becker, Emily
    de Lucas, Raul
    Belloni-Fortina, Anna
    Armesto, Susana
    Elewski, Boni
    Maes, Peter
    Oberoi, Rajneet K.
    Paris, Maria
    Zhang, Wendy
    Zhang, Zuoshun
    Arkin, Lisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (06) : 1232 - 1239
  • [38] Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study
    Li Xia
    Zheng Jie
    Pan WeiLi
    Zheng Min
    Lu Yan
    Li FuQiu
    Ding YangFeng
    Zhang JianZhong
    Li HongYing
    Rui WenLong
    国际皮肤性病学杂志（英文）, 2022, 05 (04)
  • [39] Efficacy and safety of ixekizumab in Chinese patients with moderate-to-severe plaque psoriasis: 12-week results from a phase 3 study
    Rui, Wenlong
    Li, Xia
    Zheng, Jie
    Pan, Weili
    Zheng, Min
    Lu, Yan
    Li, Fuqiu
    Ding, Yangfeng
    Zhang, Jianzhong
    Li, Hongying
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB55 - AB55
  • [40] Improvements in patient-reported outcomes (PROs) among moderate to severe plaque psoriasis patients treated with brodalumab: Results from AMAGINE-1
    Strober, Bruce
    Gordon, Kenneth
    Augustin, Matthias
    Viswanathan, Hema
    Klekotka, Paul
    Milmont, Cassandra
    Kricorian, Gregory
    Harrison, David
    Pinto, Lionel
    Nirula, Ajay
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB256 - AB256
12345